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The Journal of Immunology
Engulfment of Activated Apoptotic Cells Abolishes
TGF-b–Mediated Immunoregulation via the Induction of
IL-6
Clare A. Notley, Mark A. Brown, Jenny L. McGovern, Christine K. Jordan, and
Michael R. Ehrenstein
Phagocytosis of apoptotic cells (ACs) is usually a potent immunoregulatory signal but can also promote inflammation. In this article,
we show that administration of apoptotic dendritic cells (DCs) inhibited inflammation in vivo through increasing production of
TGF-b from intrinsic DCs and B cells. However, ACs derived from LPS-activated DCs failed to restrain inflammation because
of a short-lived but marked IL-6 response, which abolished the increase in TGF-b. Inhibition of IL-6 restored the protective anti-
inflammatory properties of aACs and the TGF-b response. DCs isolated from mice that had received resting but not activated ACs
could transfer the suppression of inflammation to recipient mice. These transferred DCs stimulated B cell TGF-b production and
relied on an intact B cell compartment to limit inflammation. These results highlight how the activation state of AC governs their
ability to control inflammation through reciprocal regulation of IL-6 and TGF-b. The Journal of Immunology, 2015, 194: 000–000.
T
he rapid clearance of apoptotic cells (ACs) by phagocytes
plays a central role in maintaining tissue homeostasis and
immune tolerance to self-Ags (1–3). Defects or disruption
to AC clearance can lead to the chronic accumulation of apoptotic
material, the initiation of inflammation, and ultimately the devel-
opment of autoimmunity or persistent inflammatory disease (4, 5).
Macrophages, dendritic cells (DCs), and B cells all contribute to
maintaining an immunosuppressive environment during the en-
gulfment of ACs via their production of IL-10 and TGF-b (6–10).
However, ACs are not always tolerogenic and can instead
promote further inflammation depending on their past experiences
(4). For instance, ACs generated during infection can alter their
normally regulatory effects through generation of inflammatory
cytokines and the induction of Th17 cells (11). Apoptotic cancer
cells are even more immunogenic than necrotic cells (12), and
when cross-presented by DCs, they induce strong CTL responses
(13, 14). Indeed, apoptotic cancer cells have been trialed for use in
cancer cell vaccines aimed at boosting immunity to cancer Ags (15,
16). Expression of CD40L by apoptotic T cells has been shown to
induce DC maturation and cross priming of CTL responses (17).
The source of the AC and the phagocytic cell involved can also
influence the immune response. Thus, apoptotic thymocytes and
splenocytes induce an IL-10–rich, suppressive environment when
engulfed by splenic cells (10, 18), whereas apoptotic DCs phago-
cytosed by resident DCs support tolerance via the production of
TGF-b (19, 20).
In this report, we provide evidence that ACs induced from pre-
viously activated DCs preferentially increase IL-6 levels, whereas
TGF-b production by DCs and B cells is promoted by resting ACs,
thereby limiting inflammation. Reciprocal regulation of TGF-b and
IL-6 by AC appears to determine the balance between inflamma-
tion and tolerance.
Materials and Methods
Mice
C57BL/6J mice and mMT mice (Jackson Laboratories, Sacramento, CA)
were bred and maintained in specific pathogen-free facilities under home
office guidelines. Mice were used between 8 and 14 wk of age. All ex-
periments were approved by the Ethical Review Committee.
Preparation of ACs
DCs were differentiated from the bone marrow of mice by culture for 5 d
with GM-CSF (Peprotech, Rocky Hill, NJ). On day 5, DCs were either left
untreated or stimulated overnight with 1 mg/ml LPS (Sigma-Aldrich, St.
Louis, MO). DCs were then cultured with 10 mM etoposide (Sigma-
Aldrich) for 5 h, and the level of apoptosis was determined by Annexin
V and propidium iodide (PI) staining. Typically, both unstimulated ACs
and activated ACs (aACs) were between 60 and 75% Annexin V+ and 8
and 11% PI+. In some experiments, DCs were stained with 1 mM PKH-26
(Sigma-Aldrich) before activation and induction of apoptosis.
Induction of arthritis
Mice were immunized with methylated BSA (mBSA; Sigma-Aldrich) as
described previously (18, 21). Some mice received 20 3 106 ACs or aACs
i.v. for 3 consecutive days after immunization. Other groups of mice re-
ceived 1.5 3 106 DCs at the time of immunization. In some experiments,
neutralization of IL-6 occurred at the time of AC transfer with i.p. injection
of 100 mg LEAF purified anti-mouse IL-6 Ab (BioLegend), or control
mice were treated with rat IgG1 isotype control (BioLegend). Clinical
score was determined by the degree of limping, where 0 = normal walking,
1 = mild limping, 2 = severe limping, and 3 = unable to put weight on leg
(18). Day 3, 6, or 7 post intra-articular injection, inguinal draining lymph
nodes and spleens were removed and stimulated with anti-CD3
mAb (0.1 ng/ml) for 72 h. Supernatants from cultures were tested for
IL-17A and IL-10 by ELISA (R&D Systems, Minneapolis, MN). In some
experiments, ACs or aACs were transferred on the day of immunization
only, and spleens were harvested and analyzed 48 h later.
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Confocal microscopy
A total of 500,000 thioglycollate-elicited peritoneal macrophages were
cultured with 2.5 3 106 ACs or aACs for 5 h on glass coverslips in the
presence of GolgiStop. Cells were washed with PBS and cell dissociation
buffer, and fixed for 10 min with methanol. Cells were stained with anti–
IL-10 PE, anti-TNF PE, or rat IgG PE isotype control (1:25 dilution in PBS
containing 2% BSA) at 4˚C overnight. Cells were washed with PBS-
Tween, and mounted and analyzed using a Leica TSC SPE confocal mi-
croscope (Leica, Buffalo Grove, IL).
In vivo engulfment
Unstimulated or LPS-stimulated, PKH-26–labeled DCs were induced to
undergo apoptosis, washed, and i.v. injected into wild type mice. One, 2, or
4 h after injection, spleens were harvested and half frozen for RNA iso-
lation and half used for flow cytometry staining. Splenocytes were stained
for CD19, CD11c, and F4/80, and the cells responsible for AC or aAC
engulfment were determined. In some experiments, spleens taken at 2 h
after injection were stained and analyzed by ImageStream. PKH-26 cells
costaining with CD11c, CD19, or F4/80 were analyzed to determine
whether they were engulfed ACs or attached to the surface of splenic cells.
In vitro engulfment
To test whether IL-6 production from phagocytes engulfing aACs was due to
carryover LPS, using 40 ng/ml M-CSF (Peprotech), we left macrophages
derived from bone marrow untreated or pretreated for 5 h with 3 mM TLR4
inhibitor CLI-095 (Invivogen, San Diego, CA). Macrophages were then
cultured for 72 h with ACs or aACs, and supernatants were taken to de-
termine IL-6 concentration by ELISA (eBioscience).
TaqMan RT-PCR
RNAwas isolated from spleens using TRIzol reagent (Invitrogen, Grand Island,
NY) and Precellys homogenization tubes (Peqlab, Sarisbury Green, U.K.).
cDNA was transcribed from 1 mg RNA using a reverse transcription kit
(Qiagen, Valencia, CA), and TaqMan RT-PCR was performed in 96 wells
using an ABI PRISM detection system. TaqMan primers and probes (Applied
Biosystems, Foster City, CA) were used to detect the expression of IL-6,
IL-10, TNF-a, TGF-b, and HPRT (endogenous control). Data were ana-
lyzed using the comparative threshold cycle (CT) method, normalizing data
to HPRT and shown as fold change relative to the no AC (untreated) mice.
Flow cytometry
Cells required for intracellular cytokine staining were cultured for 6 h in
RPMI 1640 containing PMA (Sigma-Aldrich) and ionomycin (Sigma-
Aldrich). GolgiStop (BD Biosciences) was added to the culture for the
last 4 h. Cells were surface stained with anti–CD19-PeCy7 or Pacific
Blue (BioLegend), anti–TGF-b–PE (R&D Systems), anti-CD11c FITC
or allophycocyanin (eBioscience), or anti-F4/80 allophycocyanin (eBio-
science). Cells were then washed and stained with anti-mouse IFN-g PE,
anti-mouse IL-17 Alexa Fluor 647 (eBioscience), or anti-mouse IL-10 PE
and analyzed by flow cytometry. Where possible, all gates were set using
isotype control Abs. All samples were run on the LSRII or LSR Fortessa
and analyzed using FlowJo software (Tree Star, Ashland, OR). All Abs
were purchased from BD Biosciences unless otherwise stated.
Cytokine bead array
DCs, macrophages, and B cells were sorted from the spleens of wild type
mice using the FACSAria (BD Biosciences) based on expression of CD11c,
F4/80, and CD19, respectively. A total of 200,000 cells were cultured for
24 h with 400,000 ACs or aACs at 37˚C and 5% CO2. Supernatants were
collected and 50 ml was analyzed for IL-6, TNF-a, and IL-10 using cy-
tokine bead array (BD Biosciences).
DC transfer
Forty-eight hours after AC injection, spleens were harvested and DCs
isolated using CD11c microbeads, following the manufacturer’s instruc-
tions (Miltenyi Biotech, Auburn, CA). Purities of CD11c+ cells ranged from
83 to 95%. DCs were adoptively transferred i.v. into wild type or mMT mice
at the time of immunization with mBSA/CFA. In some experiments, mice
were treated i.p. with 400 mg TGF-b R1 kinase inhibitor VI (Millipore, MA)
every 3 d from the day of DC transfer.
Statistical analysis
All data were analyzed using GraphPad Prism software (San Diego, CA).
The statistical analyses performed are noted with the corresponding data.
FIGURE 1. aACs induce production of the proinflammatory cytokines IL-6
and TNF-a in vitro. (A) Peritoneal macrophages were cultured for 6 h alone (No
AC) or with apoptotic DCs (AC) or LPS-activated apoptotic DCs (aAC) and then
stained for IL-10, TNF-a (red), and DAPI (blue) and imaged using a Leica TSC
SPE confocal microscope (original magnification 340). Arrows show cytokine
production. Bar charts show combined data of the mean 6 SEM percentage of
cytokine-producing cells per field from six independent experiments. (B) Splenic
DCs, B cells, and macrophages were cultured for 24 h alone (Nil) or with ACs or
aACs. Supernatants were collected, and IL-10, TNF-a, and IL-6 levels were de-
termined. Graphs show mean 6 SEM of pooled data from three independent
experiments. (C) Bone marrow–derived macrophages were left untreated (M) or
pretreated with a TLR4 inhibitor (i). Macrophages were subsequently cultured
with 0.01 mg/ml LPS, ACs, or aACs for 72 h, and IL-6 concentration was deter-
mined by ELISA.Graph showsmean6SEM from six independent experiments.
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In general, data were analyzed by one-way ANOVA followed by Bonferroni
post hoc testing for multiple comparisons or paired or unpaired t test.
Results
Resting and aACs differentially regulate the production of
anti-inflammatory and proinflammatory cytokines
We first sought to identify a system in which we could test and
compare the ability of resting and activated cells that have un-
dergone apoptosis to induce a differential cytokine response by
phagocytes during clearance. Resting (ACs) and LPS aACs were
therefore generated from bone marrow–derived DCs. DC activa-
tion was associated with an upregulation of CD80, CD86, and
MHCII expression compared with resting DCs. LPS activation of
DCs did not upregulate CD40L, nor did it affect the apoptotic
phenotype (determined by Annexin V and PI staining; data not
shown) of the aACs compared with the ACs after culture with
etoposide to induce apoptosis.
To determine the cytokines induced in response to ACs or aACs,
we cultured thioglycollate-elicited peritoneal macrophages (Fig.
1A) or splenic DCs, B cells, or macrophages (Fig. 1B) in vitro
alone or with ACs or aACs. Whereas ACs and aACs induced equal
amounts of IL-10 (Fig. 1A, 1B), aACs preferentially enhanced
the production of the inflammatory cytokines TNF-a and IL-6
(Fig. 1A, 1B). To confirm that the inflammatory cytokine pro-
duction was not due to LPS carryover from the cultures containing
LPS, we cultured bone marrow–derived macrophages with ACs
and aACs in the presence of a TLR4 inhibitor. Inhibition of TLR4
had no significant effect on the production of IL-6 by aACs but
could abolish the production of IL-6 induced by stimulation with
LPS (Fig. 1C). i.v. injection of 20 3 106 ACs or aACs into naive
mice confirmed that both aACs and ACs induced the production
of IL-10 from splenocytes; however, aACs also increased the
production of TNF-a and IL-6 (Fig. 2A). Notably, there was an
early short burst of IL-6 production, which increased 50-fold
immediately after transfer of aACs. In addition, we observed that
ACs, but not aACs, induced TGF-b production during a 2-h
period after transfer.
To determine whether the responses observed in vivo were due to
the differential engulfment by phagocytic cells in the spleen, we
transferred PKH-26–labeled ACs and aACs i.v., and the migration
and engulfment of cells within the spleen were detected by flow
cytometry. Engulfment of ACs and aACs, primarily by macro-
phages and DCs, was evident at 1, 2, and 4 h after transfer (Fig.
2B). The contribution of the various phagocytic cells within the
spleen in the removal of ACs and aACs was similar, suggesting
that the differences observed in cytokine production were not due
to engulfment by specific cell types. Cells were also analyzed by
ImageStream, confirming that ∼80% of the ACs costaining with
DC or macrophage markers were internalized rather than attached
to the engulfing cell (Fig. 2C, 2D).
aACs are unable to suppress the development of inflammatory
arthritis
It has previously been shown that transfer of thymically derived
ACs at the time of immunization can suppress the development and
FIGURE 2. aACs induce production of the proinflammatory cytokines
IL-6 and TNF-a in vivo. (A) C57BL/6 mice were left untreated or injected
with ACs or aACs and spleens snap-frozen 1, 2, or 4 h later, and the fold
increase in IL-10, TGF-b, TNF-a, and IL-6 mRNA production was de-
termined in mice treated with ACs or aACs compared with untreated mice.
All data were normalized to HPRT. Graphs show mean 6 SEM of pooled
data from three independent experiments. (B) PKH-26+ ACs or aACs were
injected into mice, and splenic cells responsible for the engulfment of ACs
and aACs were determined by gating on the PKH-26+ cells and analyzed
for coexpression of F4/80 to identify macrophages, CD11c to identify
DCs, and CD19 to identify B cells. FACS plots show representative data,
and graphs show the mean 6 SEM percentage of ACs and aACs engulfed
by B cells, DCs, or macrophages. Data are pooled from four independent
experiments. (C) Cells were further analyzed using ImageStream to de-
termine the percentage of PKH-26+ cells engulfed in the spleen. Graph
shows data from two independent experiments from six individual mice. (D)
Images showing engulfment by DCs (top panel) and macrophages (bottom
panel) are representative of the data (original magnification 340). The
markers/stains used in (D) are indicated above the lanes in the figure.
Details of the fluorescent labels attached to CD11c and F4/80 are given in
the Materials and Methods (CD11c-FITC and F4/80-APC).
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severity of inflammatory arthritis through the production of IL-10
(10, 18). Given the differences we found with respect to cytokine
production between ACs and aACs, we next sought to investigate
whether both are equally potent at suppressing inflammation
in vivo. We used the Ag-induced arthritis (AIA) model, which is
IL-17 dependent (22, 23). Although ACs derived from resting DCs
suppressed the development of AIA, activation of the DCs with
LPS before apoptosis induction resulted in an inability to modu-
late arthritis development (Fig. 3A). ELISA (Fig. 3B) and flow
cytometry (Fig. 3C–F) data show that suppression of arthritis was
determined by the balance of IL-17 and TGF-b production, where
decreased production of IL-17 by draining lymph node cells and
an increase in TGF-b production by the splenocytes were pro-
tective. aAC transfer was neither able to suppress IL-17 responses
FIGURE 3. Activation of ACs abolishes the ability of ACs to induce TGF-b. (A) Arthritis was monitored in mice left untreated (No AC) or injected with
AC or aAC on the day of immunization and for a further 2 consecutive days before intra-articular injection of mBSA to induce inflammation in the knee.
Lymph nodes and spleens were harvested on day 7 after knee injection. LN cells were analyzed for IL-17 production by (B) ELISA after no stimulation
(Nil) or stimulation with anti-CD3 mAb (aCD3) and (C) flow cytometry. IFN-g production in the LNs was also determined by flow cytometry after gating
on lymphocytes (C). IL-10 production by the spleen was assessed by (B) ELISA and (D) flow cytometry, after gating on lymphocytes. TGF-b production by
splenic B cells (E) and DCs (F) was analyzed by flow cytometry. Live lymphocytes were gated; then CD11c+ or CD19+ populations were gated and assessed
for TGF-b production. n = 12 pooled from 4 independent experiments. (G) Mice were left untreated (No AC) or injected with AC or aAC, then immunized
and spleens harvested 48 h later. The production of TGF-b by DCs and B cells was determined by flow cytometry, gated as mentioned earlier. Histograms
show pooled data from 4 independent experiments; n = 12. FACS plots are representative data.
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in the lymph node nor boost TGF-b production by splenic B cells
and DCs. IL-10 production by splenocytes was upregulated by
aACs to a similar level observed by resting ACs (Fig. 3B, 3D).
Suppression of IFN-g was variable between studies, consistent
with a previous publication that ACs do not significantly inhibit
Th1 cells during AIA (18) (Fig. 3C). Upregulation of TGF-b
mRNA was observed within 4 h of AC transfer (Fig. 2A). We
therefore transferred mice with 203 106 ACs or aACs, immunized
with mBSA/CFA, and analyzed the spleens 48 h later to further
dissect the ability of ACs and aACs to modulate TGF-b production
during the initiation of inflammation. At 48 h after transfer, a sig-
nificant increase in the percentage of TGF-b–producing DCs and,
to a lesser extent, B cells was observed in the spleens of AC-treated
mice compared with aAC-treated mice (Fig. 3G).
aACs are unable to suppress the development of inflammatory
arthritis due to the induction of IL-6 and inhibition of TGF-b
production
We next sought to determine whether shifting the balance of
proinflammatory and anti-inflammatory cytokines after aAC
transfer could restore the protective immune response that was
observed with ACs. Because IL-6 increased greatly in the spleens
of mice injected with aACs compared with ACs (Fig. 2A), we
transferred aACs alone or in combination with IL-6 blockade at
the time of immunization to determine the role of IL-6 in mod-
ulating immune suppression. Inhibition of IL-6 production at the
time of aAC transfer resulted in suppression of AIA (Fig. 4A) and
IL-17 responses (Fig. 4B), as observed after AC transfer. Further-
more, IL-6 blockade permitted the induction of TGF-b production
by splenic B cells (Fig. 4C) and DCs (Fig. 4D), demonstrating that
TGF-b production is inhibited by IL-6. Taken together, these results
suggest that resting ACs suppress inflammation via TGF-b, whereas
aACs promote IL-6 production, which blocks TGF-b production
and its anti-inflammatory effects.
TGF-b–producing DCs induced in response to resting ACs can
transfer their protective effects
To confirm whether the ability of ACs to suppress AIAwas due to
the induction of TGF-b–producing splenic DCs, we isolated
CD11c+ DCs from untreated mice and mice treated for 48 h with
ACs or aACs and adoptively transferred them into C57BL/6 mice
at the time of immunization with mBSA (Fig. 5A). Transfer of
1.5 3 106 DCs from AC-treated mice (AC DCs) on the day of
immunization was sufficient to suppress the severity of AIA. In
contrast, DCs from untreated (Nil DC) or aAC-treated mice (aAC
DC) were unable to modulate the disease severity (Fig. 5B).
Blockade of TGF-b from the day of AC DC transfer resulted in
the abrogation of the protective effects of AC DCs (Fig. 5C),
demonstrating that the suppressive properties of AC DCs are
mediated by their ability to produce TGF-b. Interestingly, we
observed that the transfer of AC DC into wild type mice increased
the production of TGF-b from B cells (Fig. 5D), as was observed
after direct transfer of ACs, although the DCs were more potent
inducers of B cell TGF-b than ACs (Fig. 3C). To identify a role
for TGF-b–producing B cells in the suppression of arthritis, we
adoptively transferred AC DCs into WT or B cell–deficient mMT
mice. Suppression of disease by AC DCs was abrogated in mMT
mice (Fig. 5E), suggesting that after AC transfer, TGF-b–pro-
ducing DCs can, in turn, induce B cell TGF-b production and
together contribute to the suppression of inflammation.
Discussion
Maintenance of immune homeostasis and tolerance to self-Ags is
dependent on the efficient disposal of ACs and the induction of an
anti-inflammatory environment. Macrophages, DCs, and B cells
are important in the removal of AC and the induction of im-
mune tolerance. Although macrophages have a critical role in the
engulfment and clearance of ACs (6, 7), DCs and B cells maintain
tolerance, even during the onset of inflammation, via the pro-
duction of TGF-b and IL-10 (18, 24, 25). Indeed, a recent study
has shown that splenic metallophilic macrophages recruit regula-
tory T cells and DCs in response to ACs, maintaining immune
tolerance to self-Ags (26). Our data extend these findings and
demonstrate that resting ACs induce TGF-b production by DCs,
which, in turn, drives the production of TGF-b by B cells. The
consequences of ACs activated with a microbial stimulant LPS are
very different, with a failure to suppress inflammation due to an
early burst of IL-6 production that inhibits DC and B cell TGF-b.
A variety of receptors and associated pathways recognize and
respond to cell death. The stage of cell death can influence whether
a cell induces tolerance or inflammation (27). For example, the
release of HMGB1 and the level of its immunological activity can
be influenced by whether the cell has undergone apoptosis or
necrosis. Activated macrophages can release HMGB1 in response
to TLR4 activation, thereby inducing cytokine production (28). It
is possible that apoptotic DCs previously activated with LPS are
able to release or trigger the secretion of active HMGB1. Whether
this is responsible for the IL-6 production by the phagocytes in our
system remains to be determined.
Blockade of IL-6 conferred protective properties upon aAC. IL-
10 production did not differ between resting and aACs, suggesting
FIGURE 4. Activation of ACs abolishes their tolerogenic properties
through an IL-6–dependent inhibition of TGF-b. A total of 20 3 106 ACs
or aACs were given i.v. to C57BL/6 mice; in some groups, aACs were
given in combination with 100 mg anti–IL-6 Ab (aAC + aIL-6). Control
groups were i.p. injected with 100 mg anti–IL-6 (aIL-6) or isotype control
(Ig control) Abs. All groups were immunized with mBSA and CFA, and
aAC, aAC + aIL-6, and AC groups received 203 106 cells i.v. for 2 further
consecutive days (A). Six days after knee injection, LNs were analyzed for
production of IL-17 by ELISA (B), and splenic B cells (C) and DCs (D)
were analyzed for production of TGF-b by flow cytometry. Live lymphocytes
were gated; then CD11c+ or CD19+ populations were gated and assessed
for TGF-b production. Data are pooled from two independent experiments;
n = 6–8. Values in plots show the percentage of cells making the cytokine.
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that IL-10 does not contribute to the regulation of inflammation in
this setting. Indeed, it is unclear how the ongoing inflammation
avoids the suppressive effects of IL-10, but it is possible that IL-10
may be required for the suppressive effects of TGF-b to prevail.
Although overproduction of IL-6 has been associated with resis-
tance to the actions of IL-10 (29) and promotion of Th17 when
TGF-b is present (30), it is possible that production of both IL-10
and TGF-b could overcome the actions of IL-6. Notwithstanding
the role of IL-10, our data indicate that the balance between
TGF-b and IL-6 orchestrates the immune response driven by DCs
in response to ACs.
aACs induced only a very short burst of IL-6, which was sufficient
to abolish the protective TGF-b response. It is tempting to speculate
that if aACs were continuously generated rather than administered
for only a short period, as was the case in this study, this IL-6 re-
sponse could be sustained, leading to worsening inflammation. This
scenario may occur during an infection resulting in a sustained
production of TGF-b and IL-6, thereby increasing Th17 cells.
Infected neutrophils that undergo apoptosis are known to promote
inflammation via the induction of Th17 cells because of their ability
to induce TNF-a, IL-6, and TGF-b production by phagocytes (11).
A number of reports have shown that DCs can induce B cells
with suppressive properties, although these have been associated
with IL-10–producing B cells (31, 32). TGF-b production has only
rarely been associated with suppression mediated by B cells (33),
but therapeutic IL-6 blockade in patients with rheumatoid arthritis
leads to an increase in regulatory B cells producing TGF-b (34).
Our findings could have important implications regarding the
links between infection and autoimmunity. Infected ACsmay either
initiate inflammation and autoimmunity or exacerbate disease
when patients with autoimmunity suffer concomitant infections. It
is tempting to speculate that targeting IL-6, which is already
available in the clinic, may reduce the severity of inflammatory
disease during infective episodes and/or reduce the tendency of
infections to trigger an exacerbation of inflammation. In patientswith
systemic lupus erythematosus, the production of autoantibodies
targeting dsDNA and other nuclear Ags are thought to arise as ACs
are inadequately cleared by phagocytic cells (5). However, our data
suggest that ACs under certain states of activation may contribute to
the worsening disease. Therefore, enhancing the efficiency of their
removal without controlling inflammation could be detrimental.
Similarly, concurrent infections may also exacerbate disease. A
multitiered approach may be optimal involving treatment of infec-
tion, control of inflammation, and finally adequate removal of ACs.
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